Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
The liver is the dominant site of metastases for patients with metastatic colorectal cancer (mCRC). Depending on the timing of diagnosis and the biology of the disease, it is not uncommon for these patients to present with visceral crisis in the form of severe liver dysfunction. Treatment of these i...
Main Authors: | Pashtoon Murtaza Kasi, Gita Thanarajasingam, Heidi D. Finnes, Jose C. Villasboas Bisneto, Joleen M. Hubbard, Axel Grothey |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2015/420159 |
Similar Items
-
Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
by: Faisal Shahjehan, et al.
Published: (2019-09-01) -
Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
by: Vanessa Wookey, et al.
Published: (2021-06-01) -
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
by: Axel Grothey MD, et al.
Published: (2012-11-01) -
331 Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C)
by: Pashtoon Kasi, et al.
Published: (2020-11-01) -
23 Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
by: Pashtoon Kasi, et al.
Published: (2020-11-01)